Current Neuropharmacology
Title: FOREWORD
Volume: 1 Issue: 3
Author(s): Tom Salt
Affiliation:
Export Options
About this article
Cite this article as:
Tom Salt , FOREWORD, Current Neuropharmacology 2003; 1 (3) . https://dx.doi.org/10.2174/1570159033477080
DOI https://dx.doi.org/10.2174/1570159033477080 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
9
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design O-GlcNAc Modification and the Tauopathies: Insights from Chemical Biology
Current Alzheimer Research Marijuana Use in Young Adults: What Do We Know?
Current Psychopharmacology Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews Road From Nose to Brain for Treatment of Alzheimer: The Bumps and Humps
CNS & Neurological Disorders - Drug Targets Editorial
Adolescent Psychiatry ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease
Current Drug Targets Involvement of the Endocannabinoid System in Motor Disorders
Current Medicinal Chemistry - Central Nervous System Agents Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart Failure
Current Vascular Pharmacology Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology Recent Achievements in the Chemistry of 1,2-Diazines
Current Organic Chemistry Estrogen Receptors alpha and beeta Two Receptors of a Kind
Current Medicinal Chemistry RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Pharmacological Characterization of Ligands at Recombinant NMDA Receptor Subtypes by Electrophysiological Recordings and Intracellular Calcium Measurements
Combinatorial Chemistry & High Throughput Screening Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Application of Model-Based Approaches to Evaluate Hepatic Transporter-Mediated Drug Clearance: In vitro, In vivo, and In vitro-In vivo Extrapolation
Current Drug Metabolism